Literature DB >> 21192942

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples.

Margaret E Ackerman1, Brian Moldt, Richard T Wyatt, Anne-Sophie Dugast, Elizabeth McAndrew, Stephen Tsoukas, Stephanie Jost, Christoph T Berger, Gaia Sciaranghella, Qingquan Liu, Darrell J Irvine, Dennis R Burton, Galit Alter.   

Abstract

Phagocytosis can be induced via the engagement of Fcγ receptors by antibody-opsonized material. Furthermore, the efficiency of antibody-induced effector functions has been shown to be dramatically modulated by changes in antibody glycosylation. Because infection can modulate antibody glycans, which in turn modulate antibody functions, assays capable of determining the induction of effector functions rather than neutralization or titer provide a valuable opportunity to more fully characterize the quality of the adaptive immune response. Here we describe a robust and high-throughput flow cytometric assay to define the phagocytic activity of antigen-specific antibodies from clinical samples. This assay employs a monocytic cell line that expresses numerous Fc receptors: including inhibitory and activating, and high and low affinity receptors--allowing complex phenotypes to be studied. We demonstrate the adaptability of this high-throughput, flow-based assay to measure antigen-specific antibody-mediated phagocytosis against an array of viruses, including influenza, HIV, and dengue. The phagocytosis assay format further allows for simultaneous analysis of cytokine release, as well as determination of the role of specific Fcγ-receptor subtypes, making it a highly useful system for parsing differences in the ability of clinical and vaccine induced antibody samples to recruit this critical effector function.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21192942      PMCID: PMC3050993          DOI: 10.1016/j.jim.2010.12.016

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  49 in total

Review 1.  A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.

Authors:  Robert M Anthony; Jeffrey V Ravetch
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

2.  Phenotypic alterations and cytokine production in THP-1 cells in response to allergens.

Authors:  Masaaki Miyazawa; Yuichi Ito; Yukiko Yoshida; Hitoshi Sakaguchi; Hiroyuki Suzuki
Journal:  Toxicol In Vitro       Date:  2006-10-14       Impact factor: 3.500

3.  Monocyte p110alpha phosphatidylinositol 3-kinase regulates phagocytosis, the phagocyte oxidase, and cytokine production.

Authors:  Jimmy S Lee; William M Nauseef; Alireza Moeenrezakhanlou; Laura M Sly; Sanaa Noubir; Kevin G Leidal; Jamie M Schlomann; Gerald Krystal; Neil E Reiner
Journal:  J Leukoc Biol       Date:  2007-03-16       Impact factor: 4.962

4.  Fc receptor but not complement binding is important in antibody protection against HIV.

Authors:  Ann J Hessell; Lars Hangartner; Meredith Hunter; Carin E G Havenith; Frank J Beurskens; Joost M Bakker; Caroline M S Lanigan; Gary Landucci; Donald N Forthal; Paul W H I Parren; Preston A Marx; Dennis R Burton
Journal:  Nature       Date:  2007-09-06       Impact factor: 49.962

5.  High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons. Masking by IgG.

Authors:  P A Kozlowski; K P Black; L Shen; S Jackson
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

Review 6.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs.

Authors:  T Shantha Raju
Journal:  Curr Opin Immunol       Date:  2008-07-17       Impact factor: 7.486

7.  Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.

Authors:  Paul V Beum; David A Mack; Andrew W Pawluczkowycz; Margaret A Lindorfer; Ronald P Taylor
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.

Authors:  John O Richards; Sher Karki; Greg A Lazar; Hsing Chen; Wei Dang; John R Desjarlais
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

9.  Proteases from Schistosoma mansoni cercariae cleave IgE at solvent exposed interdomain regions.

Authors:  Akhmed Aslam; Phyllis Quinn; Richard S McIntosh; Jianguo Shi; Ashfaq Ghumra; James H McKerrow; Karen A Bunting; David W Dunne; Michael J Doenhoff; Sherie L Morrison; Ke Zhang; Richard J Pleass
Journal:  Mol Immunol       Date:  2007-07-12       Impact factor: 4.407

10.  Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis.

Authors:  Maria Allhorn; Anders I Olin; Falk Nimmerjahn; Mattias Collin
Journal:  PLoS One       Date:  2008-01-09       Impact factor: 3.240

View more
  217 in total

1.  Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Authors:  J Brian Kimble; Delphine C Malherbe; Michelle Meyer; Bronwyn M Gunn; Marcus M Karim; Philipp A Ilinykh; Mathieu Iampietro; Khaled S Mohamed; Surendra Negi; Pavlo Gilchuk; Kai Huang; Yuri I Wolf; Werner Braun; James E Crowe; Galit Alter; Alexander Bukreyev
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Determining the phagocytic activity of clinical antibody samples.

Authors:  Elizabeth G McAndrew; Anne-Sophie Dugast; Anna F Licht; Justin R Eusebio; Galit Alter; Margaret E Ackerman
Journal:  J Vis Exp       Date:  2011-11-30       Impact factor: 1.355

3.  Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.

Authors:  Austin W Boesch; James H Kappel; Alison E Mahan; Thach H Chu; Andrew R Crowley; Nana Y Osei-Owusu; Galit Alter; Margaret E Ackerman
Journal:  Biotechnol Bioeng       Date:  2018-02-01       Impact factor: 4.530

4.  Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.

Authors:  Jennifer I Lai; Anna F Licht; Anne-Sophie Dugast; Todd Suscovich; Ickwon Choi; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

5.  Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Authors:  Susan Zolla-Pazner; Rebecca Powell; Sara Yahyaei; Constance Williams; Xunqing Jiang; Wei Li; Shan Lu; Shixia Wang; Chitra Upadhyay; Catarina E Hioe; Max Totrov; Xiangpeng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

6.  Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.

Authors:  Amy W Chung; Jenniffer M Mabuka; Bongiwe Ndlovu; Anna Licht; Hannah Robinson; Yathisha Ramlakhan; Musie Ghebremichael; Tarylee Reddy; Philip J R Goulder; Bruce D Walker; Thumbi Ndung'u; Galit Alter
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

7.  Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques.

Authors:  Thomas Musich; Thorsten Demberg; Ian L Morgan; Jacob D Estes; Genoveffa Franchini; Marjorie Robert-Guroff
Journal:  Clin Immunol       Date:  2015-04-01       Impact factor: 3.969

8.  Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).

Authors:  Kathryn E Stephenson; Frank Wegmann; Frank Tomaka; Stephen R Walsh; C Sabrina Tan; Ludo Lavreys; Jessica L Ansel; Diane G Kanjilal; Kate Jaegle; Joseph P Nkolola; Lauren Peter; Rachel Fogel; Connor Bradshaw; Anna Tyler; Tatenda Makoni; Lisa Howe; Darla Quijada; Abishek Chandrashekar; Esther A Bondzie; Erica N Borducchi; Katherine E Yanosick; Jenny Hendriks; Steven Nijs; Carla Truyers; Jeroen Tolboom; Roland C Zahn; Michael S Seaman; Galit Alter; Daniel J Stieh; Maria Grazia Pau; Hanneke Schuitemaker; Dan H Barouch
Journal:  Lancet HIV       Date:  2020-02-17       Impact factor: 12.767

9.  Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

Authors:  M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

10.  A Functional Role for Antibodies in Tuberculosis.

Authors:  Lenette L Lu; Amy W Chung; Tracy R Rosebrock; Musie Ghebremichael; Wen Han Yu; Patricia S Grace; Matthew K Schoen; Fikadu Tafesse; Constance Martin; Vivian Leung; Alison E Mahan; Magdalena Sips; Manu P Kumar; Jacquelynne Tedesco; Hannah Robinson; Elizabeth Tkachenko; Monia Draghi; Katherine J Freedberg; Hendrik Streeck; Todd J Suscovich; Douglas A Lauffenburger; Blanca I Restrepo; Cheryl Day; Sarah M Fortune; Galit Alter
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.